Clinical Trial

Interleukin-2 on Active Dermatomyositis

Enrolling by Invitation Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated December 5, 2022 (before its estimated September 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this paper is to explore the effect of low-dose IL-2 on refractory dermatomyositis and immunological indexes.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-08-08; most recent amendment 2022-12-02.
Status change: Recruiting → Enrolling by Invitation 2022-12-02
Status change: Not Yet Recruiting → Recruiting 2022-11-30
Trial Details
NCT Number NCT05495321
Lead Sponsor Peking University People's Hospital
Conditions Dermatomyositis
Enrollment 240 participants
Start Date 2022-12-01
Primary Completion 2025-09-01 (estimated)
Study Completion 2026-09-01 (estimated)
Updated on ClinicalTrials.gov 2022-12-05